Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Asset Writedowns and Impairment (2017 - 2025)

Perspective Therapeutics (CATX) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Asset Writedowns and Impairment rose 17141.38% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Dec 2025, up 2702.7% year-over-year, with the annual reading at $10.0 million for FY2025, N/A changed from the prior year.
  • Asset Writedowns and Impairment hit $10.0 million in Q4 2025 for Perspective Therapeutics, up from $58000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $10.0 million in Q4 2025 to a low of -$14000.0 in Q3 2024.
  • Historically, Asset Writedowns and Impairment has averaged $2.6 million across 3 years, with a median of $192000.0 in 2023.
  • Biggest five-year swings in Asset Writedowns and Impairment: tumbled 82.21% in 2024 and later soared 17141.38% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $326000.0 in 2023, then crashed by 82.21% to $58000.0 in 2024, then skyrocketed by 17141.38% to $10.0 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CATX at $10.0 million in Q4 2025, $58000.0 in Q4 2024, and -$14000.0 in Q3 2024.